MTOR and interstitial lung disease: ILD has been reported with several classes of anticancer therapies, including chemotherapy, tyrosine kinase inhibitors (TKIs), mammalian target of rapamycin (mTOR) inhibitors, immune checkpoint inhibitors (ICIs), and ADCs, with an incidence rate ranging from 0.4% to 54%.